Tyra Biosciences to Present at the Cantor Global Healthcare Conference
Tyra Biosciences (TYRA) will present at the Cantor Global Healthcare Conference 2026 in a virtual fireside chat and one-on-one investor meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tyra Biosciences (TYRA) will present at the Cantor Global Healthcare Conference 2026 in a virtual fireside chat and one-on-one investor meetings.
The presentation is scheduled for Wednesday, September 9, 2026 at 1:00 PM ET, with the conference held in New York, NY. A live webcast and replay will be accessible via the company’s “For Investors” page on its website.
Details
News Market Reaction – TYRA
On Sep 9, the first trading day after this news, TYRA closed 17.66% below the previous close. Argus tracked a peak move of +16.6% during that session. Argus tracked a trough of -33.1% from its starting point during tracking. Our momentum scanner recorded 23 alerts for this stock that day. Relative volume reached 624.3x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 9 session.
Key Terms
fgfr technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Cantor Global Healthcare Conference 2026
Format: Virtual fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, September 9, 2026 at 1:00 PM ET
Location: New
A live webcast of the presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for low-grade upper tract urothelial carcinoma, low-grade intermediate-risk non-muscle invasive bladder cancer and achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, California.
For more information, please visit www.tyra.bio and engage with TYRA on LinkedIn.
Contact
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-the-cantor-global-healthcare-conference-302872416.html
SOURCE Tyra Biosciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How can investors access Tyra Biosciences’ presentation and replay from the Cantor Global Healthcare Conference 2026?
A live webcast of Tyra Biosciences’ presentation can be accessed by visiting the “For Investors” page on the company’s website, where a replay will also be available following the event.